ABVC: ABVC BioPharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 12.87
Enterprise Value ($M) 14.67
Book Value ($M) 0.72
Book Value / Share 0.05
Price / Book 17.77
NCAV ($M) -4.64
NCAV / Share -0.31
Price / NCAV -2.78

Profitability (mra)
Return on Invested Capital (ROIC) -1.25
Return on Assets (ROA) -0.34
Return on Equity (ROE) -0.65

Liquidity (mrq)
Quick Ratio 0.33
Current Ratio 0.33

Balance Sheet (mrq) ($M)
Current Assets 2.18
Assets 7.54
Liabilities 6.82
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.51
Operating Income -4.71
Net Income -4.90
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -1.81
Cash from Investing 0.00
Cash from Financing 1.98

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Lind Global Fund II LP 9.90 15.22

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-17 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-21 26,076 176,195 14.80
2025-04-17 42,886 222,816 19.25
2025-04-16 29,804 275,821 10.81

(click for more detail)

Similar Companies
ABEO – Abeona Therapeutics Inc. ACB – Aurora Cannabis Inc.
ACHV – Achieve Life Sciences, Inc.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.